Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Outcomes in Multiple Myeloma Patients Evaluated

Ann Hematol; ePub 2016 Dec 2; Berenson, et al

Publish date:: December 14, 2016

There appears to be marked improvement in overall survival in people with multiple myeloma, according to a study involving 264 individuals.

Participants all had multiple myeloma with an initial visit occurring between 2004 and 2014. They had treatment at a clinic that specialized in the disorder. Investigators looked at progression-free, overall, and 5-year overall survival. Among the results:

Progression-free survival for frontline treatments was ~14 months; for salvage and all treatments it was 4.6 and 5.5 months, respectively.
Median overall survival in all patients was 98 months.
5-year survival rate was 74%.

The authors noted that these findings should help physicians predict outcomes.

Citation:

Berenson A, Vardanyan S, David M, et al. Improved clinical outcomes for multiple myeloma patients treated at a single specialty clinic. [Published online ahead of print December 2, 2016]. Ann Hematol. doi:10.1007/s00277-016-2888-3.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Multiple Myeloma

Caregiver burden of outpatient ASCT for multiple myeloma comparable with inpatient transplant,

Study found dual-targeted CAR T highly active against relapsed/refractory multiple myeloma,

Durable responses with anti-BCMA CAR T-cell for multiple myeloma,

Circulating miRNA could be a potential biomarker for early diagnosis of MM,